Specialty
Certifications
Psychiatry, American Board of Psychiatry and Neurology
Clinical Focus
Education
MD, Carol Davila University of Medicine and Pharmacy
Master of Medical Science, Harvard Medical School
MedicineInternship, Internal Medicine
Massachusetts General HospitalResidency, Psychiatry
Massachusetts General HospitalFellowship, Psychiatry
University of Geneva
Biography
Dr. Dan Iosifescu is the Director of the Mood and Anxiety Disorders Program and Associate Professor of Psychiatry and Neuroscience at Mount Sinai Medical School. He comes from Boston where until April 2010 he was Associate Professor of Psychiatry at Harvard Medical School and Director of Translational Neuroscience in the Depression Clinical and Research Program and Site Director of the Bipolar Trials Network, both at Massachusetts General Hospital. Dr. Iosifescu’s research is focused on biological markers of treatment outcome in mood disorders, using neuroimaging (MRI, MRS) and neurophysiology (quantitative EEG) techniques to investigate structural, biochemical, and functional brain abnormalities in mood disorders and their impact on clinical treatment. As MGH Site Director of the NIMH Bipolar Trials Network, Dr. Iosifescu has led the day-to-day operationof the MGH site as part of an internationally known clinical research network. Dr. Iosifescu is also interested in the impact of co-morbid medical illness, especially vascular disease, on treatment outcome in mood disorders. Dr. Iosifescu has continuously received independent funding from NIMH since 2003 (as well as from private foundations); he is currently funded by an NIMH R01 to study treatments for cognitive deficits in bipolar disorder.
After receiving his M.D. from the Institute of Medicine and Pharmacy in Bucharest, Romania, Dr. Iosifescu completed his internship and psychiatry residency at Massachusetts General Hospital and McLean Hospital, serving as chief resident in consultation-liaison psychiatry. His research training included a neuroimaging fellowship in the Neuroscience Laboratory at Harvard Medical School, a psychopharmacology fellowship in the MGH Mood and Anxiety Disorders Institute, and a fellowship in the Clinical Investigator Training Program at Harvard and MIT. In parallel Dr. Iosifescu received a Master of Medical Science degree from Harvard University.
Dr. Iosifescu has authored more than 50 papers in peer-reviewed medical journals, nine book chapters and more than 50 abstracts. He received a series of prestigious prizes: the NARSAD Young Investigator Award (which he received twice), the Kaplen Award and the Livingston Award from Harvard Medical School, the APA Young Investigator Award, the NCDEU New Investigator Award, and a National Institute for Mental Health K23 Career Development Award. Dr. Iosifescu was also designated among the “Top Doctors in Boston” by Boston Magazine (2006 and 2008) and among the “Best Doctors in America” in all editions of “Best Doctors” since 2005.
In the News
Dr. Iosifescu discusses depression and bipolar disorder in The Daily News feature The Daily Check Up.Clinical Trials
- A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants
- A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/day and 100 mg/day of EB-1010 among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- Evaluation of Low Emission Neosync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter Randomized, Double-Blind, Sham-Controlled Trial
- A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of RO4995819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment
- Evaluation of NK1 Antagonist in Post-Traumatic Stress
- A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant
- A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil deep Transcranial Magnetic Stimulation (TMS) in conjunction with mood stabilizers in Subjects with Bipolar Depression
- Optimization of IV Ketamine in Treatment-Resistant Major Depression
- The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder
- Minocycline for Bipolar Disorder
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Iosifescu during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Sunovion Pharmaceuticals Inc.
Scientific Advisory Board:
- Otsuka Pharmaceutical Co., Ltd.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Servier
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor E Level Room 17
1428 Madison Avenue
New York, NY 10029
Fax: 212-241-3354
1428 Madison Avenue
Atran Bldg. E Level Room ABE-17
New York, NY 10029
Fax: 212-241-3354
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- Personal Check
- Cash
- Other